Organic Active Ingredients TRIZ Cases

Using cannabinoid-reduced cannabis residue alone or with hempseed hull, this case shows a new prebiotic source that promotes beneficial gut microbes.

A metformin and Chir99021 combination suppresses collagen deposition and inflammation to treat fibrosis and limit tissue damage.

A one-pot sequence merges phosphorane formation and Wittig reaction to raise benzopyranone yield, cut impurities, and support scale-up.

Brain-region Aβ and tau interaction scores help predict Alzheimer's treatment response and support more personalized therapy selection.

Targeted RNAi silences XDH expression in hepatocytes, offering urate lowering for gout and hyperuricemia with fewer side effects.

A benzoimidazole sulphate salt protects motor neurons and neuromuscular junctions by modulating Tau, progranulin, and TDP-43.

A six-strain probiotic with glutamine targets the gut-brain axis to ease OCD symptoms when standard antidepressants show limited response.

Poziotinib overcomes steric hindrance and TKI resistance in HER2 exon 21 mutant cancers, enabling potent low-dose inhibition and tumor regression.

A dual MDH1/MDH2 inhibitor blocks mitochondrial respiration and cancer cell growth by disrupting a key metabolic pathway.

An aqueous flocculated suspension using sorbitan esters and polysorbate 20 improves antipsychotic injectability, resuspendability, and site tolerance.

Synthetic kava analogs inhibit TNF-α and reduce inflammation, offering a lower-cost alternative to biologics for periodontitis and arthritis.

A selective amide scaffold targets JAK1 while sparing JAK2, aiming to treat JAK1-mediated disease with lower dose-limiting toxicity.

A buffered micronized apixaban suspension avoids surfactants and phase change while preserving crystallinity, dissolution, and oral stability.

Mesoporous zirconia carriers load and release antimicrobials inside biofilms, improving eradication while lowering dose and side effects.

Retinal viral-vector delivery with cell-specific promoters targets locus coeruleus pathways without direct brain surgery for nervous system disorders.

Novel endocyclic pyrimidinone compounds inhibit Lp-PLA2 to reduce oxidative stress and inflammation in neurodegenerative and cardiovascular disease.

Camphorquinone-initiated hyaluronic acid hydrogel extends joint residence and lubrication while avoiding toxic crosslinker purification.

A saliva-permeable nicotine pouch uses water-insoluble fiber and alkaline pH control to speed release while staying small and discreet.

A hydrophilic core in a hydrophobic phase uses osmotic pressure to stabilize nicotine release and improve absorption consistency.

A novel resiquimod monosulfate anhydrate crystal form improves stability, dissolution consistency, and bioavailability for cancer treatment.

Positively charged ruthenium complexes use 3D binding geometry to improve galectin-1 selectivity and inhibition for cancer, fibrosis, and HIV.

Selective imidazopyridine and triazolopyridine TLR9 inhibitors address fibrosis while improving stability, bioavailability, and side-effect control.

A novel compound BAB159 and its polymyxin E combination address multidrug resistance with broad-spectrum antibacterial and antifungal activity.

RAC2 G12V delivery ablates hematopoiesis for bone marrow transplantation while avoiding the toxicity of chemotherapy and radiotherapy.

Specific indole amide compounds inhibit IDO to block tryptophan conversion, helping restore immune function across cancer and inflammatory disease.

Specific lithium benzoate cocrystals tune water solubility to extend lithium release while preserving bioavailability and reducing hygroscopicity.

Ester-linked tryptamine prodrugs improve oral bioavailability and stability, then hydrolyze in vivo to active 5HT2A agonists for depression.

Small molecules targeting a defined PCSK9 binding pocket enable oral LDL-C lowering with fewer antibody-related reactions.

Self-inactivating CRISPR-Cas vectors improve repeat-disorder editing by limiting expression time, reducing off-target activity, and preserving delivery efficiency.

Selective imidazoquinazoline A2A antagonists target motor symptoms in Parkinson's disease while aiming to limit non-motor side effects.

Peptide Smad3 inhibitors improve selectivity over small molecules to suppress cancer cell growth, invasion, and metastasis.

Strategic fluoro nucleotide placement improves blood and liver stability while maintaining hepatocyte-targeted gene silencing with fewer off-target effects.

Combined oral minoxidil and finasteride simplify hair loss treatment, improving compliance while enhancing hair growth and reducing shedding.

A resistant starch, oat beta-glucan, and resistant dextrin blend helps stabilize blood sugar, improve satiety, and support digestive health.

A Formula I compound paired with hyodeoxycholic acid helps restore ovarian function by lowering FSH, raising estrogen, and reducing oxidative stress.

Bifunctional compounds recruit E3 ligases to ubiquitinate and degrade tau protein, addressing the lack of effective tau-targeting therapies.

Novel isoquinolinone salt crystal forms improve membrane permeability and drug exposure, enabling longer-lasting intraocular pressure reduction.

Specific insulin chain modifications plus iloprost, citrate, EDTA, and polyphosphates speed absorption while limiting fibril formation.

mRNA encoding VZV antigens boosts earlier antibody responses and broader immunity while avoiding live-virus and DNA vaccine risks.

A single-serve d-mannose drink balances effective dosage with manageable liquid volume to improve timely use for urinary tract health.

A buffered naloxone nasal composition with glycerin improves storage stability while preserving rapid overdose reversal and easy repeat dosing.

CCR1 antagonists help inhibit pancreatic tumor growth and support patient stratification using CCR1 expression and macrophage infiltration.

Pyrido[2,3-d]pyrimidin-7-one compounds tune dual or selective RIPK2 and ALK2 inhibition to address inflammatory, bone, and cancer pathways.

A heterocyclic TRPC5 inhibitor case showing how structure changes improve liver microsome stability and clinical pharmacokinetic properties.

A PEG-tuned lipid nanoparticle enables low-invasive transnasal nucleic acid delivery to brain tissue while limiting liver accumulation.

Specific KRAS inhibitor compounds target G12C and G12D mutations to improve treatment potential across pancreatic, lung, and colorectal cancers.

A small-molecule inducer boosts secretion of correctly folded Z A1AT, addressing misfolding and low active A1AT levels in AATD.

Selective β2 receptor antagonist ICI 118,551 targets glioblastoma stemness and viability to delay progression despite resistance and BBB limits.

Novel BTK-targeting imidazopyridinone derivatives improve therapeutic efficacy while addressing variable patient response in autoimmune disease and cancer.

Modified oligonucleotides bind PLP1 RNA to lower toxic PLP1 expression and help relieve Pelizaeus-Merzbacher disease symptoms.

Local surfactant-budesonide delivery helps prevent BPD in preterm neonates while limiting systemic steroid side effects.

Adhesive unimolecular micelles are painted onto vessel adventitia to localize drug delivery and reduce intimal hyperplasia without bulky hydrogels.

Novel quinazoline derivatives inhibit FLT3 to expand targeted treatment options for acute myeloid leukemia.

A combined compound and bacterial-strain composition treats obesity by restoring gut microbiome balance and reducing food addiction.

Selective DDR1/DDR2 inhibitors use tetrahydrothienopyridine chemistry to improve inhalation profile and limit systemic exposure in lung fibrosis.

Selective receptor ligation targets overexpressed markers on virus-infected T lymphocytes to kill infected cells, lower viral load, and limit side effects.

A receptor-targeted exatecan ligand-drug conjugate improves solid tumor killing while reducing toxicity to normal cells.

Dual HDGF-VEGF targeting in one ocular antibody aims to curb abnormal cell and vascular growth with fewer limits than monthly anti-VEGF injections.

Formula I compounds selectively inhibit IRAK4 signaling to curb proinflammatory cytokine production in rheumatoid arthritis, tumors, and related disorders.

Small molecules selectively inhibit NIK to treat cancer and inflammatory disease while limiting broad immunosuppression.

Converting Compound A into a crystalline HCl salt resolves poor free-base stability and enables solid pharmaceutical dosage forms.

Targeting PARP7 with pyridazinone compounds helps reverse immune evasion by restoring Type I interferon signaling and T cell tumor killing.

A self-degrading Alvocidib prodrug enables remote liposome loading, sustained release, improved pharmacokinetics, and fewer side effects.

Topical CoQ10 helps chronic epidermolysis bullosa wounds shift from persistent inflammation to healing, reducing blister and wound size.

Heteroaryl methacrylic acids improve fumarate metabolic stability while reducing cytokine release and activating NRF2 for anti-inflammatory effects.

A polyphenol and high-DP oligosaccharide blend boosts Akkermansia and other beneficial gut bacteria while reducing GI discomfort.

Selective AKT-targeting compounds suppress cancer cell growth while avoiding the side effects and feedback issues seen with PI3K or mTOR inhibition.

Cyclodextrin and bicarbonate improve meloxicam solubility and bioavailability, enabling faster, sustained pain relief with rizatriptan.

Small-molecule FAO inhibitors suppress intracellular Mycobacteria by shifting host metabolism and boosting autophagy and mitochondrial ROS.

Modified mitragynine derivatives improve opioid receptor modulation for pain relief while reducing side effects and tolerance.

Alkali metal salt formation and particle-size milling improve solubility and systemic exposure of an AMPK-activating benzamide compound.

Topical or oral niacin promotes regeneration of bone resorbed by periodontitis or rheumatoid arthritis without relying on costly growth factors.

These isoquinoline sulfonamides target IgE-FcεRI binding to curb histamine release and treat allergic and asthma-related responses.

Direct allosteric AMPK activators based on substituted resorcylic acid improve metabolic treatment potential while avoiding mitochondrial toxicity.

Recombinant lymphotoxin alpha targets leukemic stem cells to overcome drug resistance and enable durable remission in myeloid leukemia.

Nucleophilic topical compounds scavenge cyanate from excess urea to reduce skin protein damage, dryness, itching, and pH imbalance.

Violacein-based feed compositions suppress Eimeria invasion and growth while avoiding resistance and residue issues in livestock coccidiosis.

CD200AR ligands counter tumor-driven immune suppression by downregulating PD-1 and CD200R1, improving vaccine response and tumor regression.

A mixed PEG-propylene glycol-povidone fill raises naproxen loading while maintaining pH control and soft gel shell compatibility.

Specific aromatic amino acids plus vitamin B6 improve skeletal muscle mass, strength, and function while avoiding costly protein supplements.

A non-aqueous cefovecin suspension uses propylene glycol dicaprylate/dicaprate and benzyl benzoate to limit caking while keeping injection easy.

A hyperbranched maltodextrin structure with high 1→6 linkages resists α-amylase digestion while maintaining soluble fiber content.

Benzene-1,3,5-tricarboxamide ester lipids stabilize lipid nanoparticles for efficient mRNA delivery while reducing oxidation-linked cytotoxicity.

A specific oral estetrol dose promotes hair growth in menopausal hair loss while aiming to avoid the safety limits of estrogen therapies.

Heating microbial cells at alkaline pH, then applying pH shock cycles, separates lipids without organic solvents, cutting waste and processing time.

Combining beta-glucan with a CD40 agonist boosts T cell-dependent anti-tumor immunity in poorly immunogenic pancreatic cancer.

Conjugated phosphorothioated oligonucleotides improve selective STAT3 and CEBPA modulation while supporting systemic delivery and immune stimulation.

Modular sigma-1 receptor agonist compounds improve receptor affinity and neuroprotection for cognitive and neurodegenerative disorders.

Selective HPK1 inhibitor compounds modulate T-cell and B-cell responses to support cancer treatment while limiting autoimmune risk.

Targeting overexpressed lncRNA LETN suppresses liver cancer cell growth by disrupting NPM1-linked rRNA production and nucleosome assembly.

Ginkgolide A offers a low-dose autism treatment approach that alleviates social, communication, and repetitive behavioral defects.

Stable mesylate, gentisate, and maleate cytisine salts enable lactose formulations with longer shelf life and less packaging burden.

A removable stereodirecting group enables intramolecular cyclization of tricyclic pyridone intermediates with high yield and optical purity.

Novel aryl glucoside SGLT1 inhibitors lower blood glucose through intestinal transport blocking, helping patients with renal impairment.

A benzofuran N-acylhydrazone derivative blocks tubulin polymerization to trigger apoptosis while improving solubility and activity in resistant cancer cells.

A biocompatible polymer with hyaluronic acid improves skin hydration and wrinkle reduction with longer-lasting effects and fewer applications.

A CBP/p300 CH1-domain modulator induces senescence or apoptosis in p53/Rb-defective cancers that resist current therapies.

NR4A1 agonists offer a non-opioid route to resolve post-operative and chemotherapy-induced neuropathic pain while reducing neuroinflammation.

Structured psilocybin dosing with pre- and post-session psychological support improves treatment adequacy for anxiety and related disorders.

Polyethylene glycol replaces ethanol in an aprepitant injection emulsion, improving storage stability and enabling use in ethanol-intolerant patients.

A cardiolipin-targeting peptidomimetic helps protect neurons, delay ALS symptom onset, and reduce axonal damage.

New antiparasitic compounds target T. gondii tissue cysts to treat chronic infection while reducing toxicity and allergic reactions.

Small molecules stabilize the GRB2 dimer interface to suppress RAS/MAP kinase signaling and support targeted cancer treatment.

An osmotic tablet uses a semipermeable membrane and push layer to sustain deutetrabenazine levels over 24 hours with once-daily dosing.

Hydrogel carriers localize immunosuppressive agents around peripheral nerve allografts to support regeneration while avoiding systemic risks.

A lipid and organic solvent composition keeps dutasteride levels stable for over a month while preventing precipitation and local irritation.

New indole and indazole TLR7/8/9 inhibitors improve stability, bioavailability, and therapeutic index for inflammatory disease treatment.

A xyloglucan core and pH-responsive coating limit small-intestine release and improve reliable colonic API delivery.

A carrier-based solid dispersion improves P2X4 inhibitor dissolution and stability while keeping impurities low and supporting better pharmacokinetics.

Targeting 4G4G and 4G5G PAI-1 genotypes, soy isoflavones help prevent asthma by lowering PAI-1 and airway inflammation.

Novel Formula (I) compounds improve JAK1 selectivity to treat asthma or COPD while reducing off-target JAK side effects.

Polymer binders capture uric acid in the gastrointestinal tract to lower serum levels and treat gout with fewer side effects.

A defined L-serine crystal form cuts moisture uptake while preserving fast dissolution, enabling stable storage and better pharmaceutical use.

Compounds built on substituted heterocycle scaffolds inhibit multiple Ras mutants and wildtype Ras to address low G12C prevalence and resistance.

Azaquinolone compounds are tuned for PARP1 selectivity and low hERG activity to improve cancer treatment efficacy while limiting off-target toxicity.

A stable liquid losartan composition uses specific excipients to match tablet bioavailability while enabling easier oral dosing and long-term storage.

CRISPR sgRNA and modified Cas9 compositions target lncEGFL7OS, EGFL7, and miR-126 to regulate angiogenesis beyond anti-VEGF resistance.

Intralymphatic delivery of multiple β cell autoantigens with vitamin D and anti-inflammatory compounds promotes durable immune tolerance with fewer systemic side effects.

A double crystal-form change produces fine drospirenone powder without grinding, preserving crystalline stability and bioavailability.

Selective inhibition of persistent VGSC currents curbs cancer cell invasion and metastasis while preserving cardiac function.

hUCB plasma modulates inflammatory and apoptotic responses to protect motor neurons and improve mononuclear cell viability in ALS.

Non-polymeric hydrophobic excipients replace complex OCAS matrices to give mirabegron extended release with stable dissolution for overactive bladder treatment.

Blending HMO syrup with GOS, FOS, or PDX creates a storage-stable, microbially safe liquid that avoids crystallization and drying.

High-dose NK1R antagonists such as aprepitant show human anti-cancer efficacy by inducing apoptosis and reducing tumor size.

Targets oxidative stress and amyloid aggregation to stabilize lens proteins, reduce disulfide bonds, and reverse presbyopia and cataracts.

Zirconia catalysts with high surface area convert c-CHDA to high-trans CHDA at lower cost, avoiding hard-to-handle thermal products.

AAV-delivered SOD expression protects inner ear hair cells from oxidative stress, enabling sustained prevention of noise, aging, and ototoxic hearing loss.

A super-chilled dextrose-salt ice slurry freezes subcutaneous fat for deeper reduction without general anesthesia or liposuction.

Liver-targeted polymethine dye delivery directs PKC inhibitors to treat septic cholestasis while reducing systemic immune suppression.

Controlled HPBCD substitution patterns overcome isomer mixtures to improve cholesterol solubilization and delivery for therapeutic use.

Targeted dsRNA silences AGT mRNA to lower angiotensinogen levels, offering a more specific route for hypertension treatment with fewer side effects.

Orally bioavailable estrogen receptor modulators block both AF1 and AF2, overcoming partial agonism and resistance in ER-associated disease treatment.

Dendrimer cannabinoid conjugates bypass first-pass metabolism to improve bioavailability and target neurons and activated microglia.

Modified branched siRNA targets SNCA mRNA for CNS delivery, improving stability and lowering alpha-synuclein in synucleinopathies.

Phosphorothioate and 2'-O-methyl miR-25 mimetics improve FKBP14 and ADAM-17 repression to better inhibit TGF-β-driven collagen in liver fibrosis.

A modified-release oral minoxidil formulation sustains serum levels to support hair regrowth while limiting rapid absorption and peak-related adverse effects.

Nanodomain topical formulations form a film on nails or skin, prolong antifungal release, improve keratin penetration, and limit systemic side effects.

Pyridine-N oxide acetamides inhibit IL-17 while improving oral or topical delivery through better solubility and in vivo exposure.

An intranasal diazepam formulation uses alkyl maltosides and carrier excipients to improve absorption consistency and reduce adverse reactions in children.

Topical ripasudil after descemetorhexis speeds endothelial healing, restores cell density, and improves corneal clarity in FECD.

Formula A-D-Y compounds inhibit VEGF, reduce cancer drug resistance, and enable topical ophthalmic treatment for diabetic retinopathy.

Spray-dried cysteamine microparticles in a thermoresponsive gel improve eye-drop stability, reduce irritation, and extend ocular release.

A dual liquid nicotine cartridge pairs water-miscible and immiscible solvents to improve lung deposition and reduce upper airway harshness.

Targeting miR-132 with the oligonucleotide CDR132L helps reverse cardiac remodeling, improve left ventricular function, and attenuate fibrosis.

SIK-modulating compounds increase bone formation and bone mass while avoiding daily injections and lowering hypercalcemia risk in osteoporosis treatment.

Targeting mPGES-1 blocks PGE2-driven inflammation and pain, offering a new treatment approach for chronic prostatitis syndrome.

CRISPR knockout of CISH improves CAR-T cell persistence and engraftment while reducing immunogenicity and graft-versus-host disease.

Controlled pH and shear-induced protein hydrogel formation creates biodegradable microcapsules that stay stable in liquids and protect sensitive actives.

Higher-solubility purine-pyrimidine aqueous formulations cut reconstitution time and dose volume, easing administration for MDS patients.

Selective norepinephrine inhibitors such as reboxetine reduce cataplexy attacks while improving concentration and sleep quality.